Yahoo! Tech
npub1hrm…j2rr
2024-12-20 11:57:01
Author Public Key
npub1hrmeelmxktje8vy2t6axvt5ae0emvfk4v5hxrvaceky4pfmn8guqkqj2rrSeen on
wss://articles.layer3.newsPublished at
2024-12-20 11:57:01Event JSON
{
"id": "a08be04053bbe2860a3bf0b802fa12e7f9d4695a2d9449b6261861c26dab454b",
"pubkey": "b8f79cff66b2e593b08a5eba662e9dcbf3b626d5652e61b3b8cd8950a7733a38",
"created_at": 1734695821,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/novo-nordisks-next-gen-obesity-105126008.html"
],
[
"subject",
"Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints"
],
[
"published_at",
"1734691886"
],
[
"image",
"https://media.zenfs.com/en/reuters-finance.com/a5e16515936647c769392db959fe10b1"
],
[
"p",
"b8f79cff66b2e593b08a5eba662e9dcbf3b626d5652e61b3b8cd8950a7733a38",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/reuters-finance.com/a5e16515936647c769392db959fe10b1"
],
[
"t",
"Technology:perspective"
],
[
"summary",
"Novo Nordisk's CagriSema, a weekly injection, combines semaglutide and cagrilintide to suppress hunger and control blood glucose. Despite being the most advanced amylin drug candidate, the results were below expectations, wiping off $125 billion from the company's market value. The company's share price fell 27%, while rival Lilly's shares rose 7%."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqhrmeelmxktje8vy2t6axvt5ae0emvfk4v5hxrvaceky4pfmn8guq4j834n\nhttps://media.zenfs.com/en/reuters-finance.com/a5e16515936647c769392db959fe10b1\n\nhttps://finance.yahoo.com/news/novo-nordisks-next-gen-obesity-105126008.html",
"sig": "79aeebf32acfe237604830789b246d7df49b884e1692c03a83ee416cccda71be487e90689c40c8cac55e6b0da64aba3780766d25fdf9f7590cd3b5d66f91620f"
}